Effect of testosterone treatment on constitutional and sexual symptoms in men with type 2 diabetes in a randomized, placebo-controlled clinical trial

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 10, 2014, Pages 3821-3828

  Gianatti, Emily J ^a,b   Dupuis, Philippe ^a,b   Hoermann, Rudolf ^a   Zajac, Jeffrey D ^a,b   Grossmann, Mathis ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; PLACEBO; TESTOSTERONE UNDECANOATE; ANDROGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ERECTILE DYSFUNCTION; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEXUAL DYSFUNCTION; SYMPTOMATOLOGY; TERTIARY CARE CENTER; UNSPECIFIED SIDE EFFECT; AGING; ANALOGS AND DERIVATIVES; BLOOD; COMPLICATION; DRUG EFFECTS; HORMONE SUBSTITUTION; LIBIDO; MALE; MIDDLE AGED; OBESITY; TREATMENT OUTCOME;

ADULT; AGED; AGING; ANDROGENS; DEPRESSION; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ERECTILE DYSFUNCTION; HORMONE REPLACEMENT THERAPY; HUMANS; LIBIDO; MALE; MIDDLE AGED; OBESITY; PLACEBOS; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84907660608     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1872     Document Type: Article

References (29)

1. Grossmann M. Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab. 2011;96:2341-2353.
2. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab. 2004;89:5462-5468.
3. Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care. 2007;30:911-917.
4. Grossmann M, Thomas MC, Panagiotopoulos S, et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab. 2008;93:1834-1840.
5. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and metaanalysis. JAMA. 2006;295:1288-1299.
6. Corona G, Monami M, Rastrelli G, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl. 2010;34:528-540.
7. Biswas M, Hampton D, Newcombe RG, Rees DA. Total and free testosterone concentrations are strongly influenced by age and central obesity in men with type 1 and type 2 diabetes but correlate weakly with symptoms of androgen deficiency and diabetes-related quality of life. Clin Endocrinol (Oxf). 2012;76:665-673.
8. Gianatti EJ, Dupuis P, Hoermann R, et al. Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial [published online May 7, 2014]. Diabetes Care. doi:10.2337/dc-13-2845.
9. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536-2559.
10. Heinemann LA. Aging Males' Symptoms scale: a standardized instrument for the practice. J Endocrinol Invest. 2005;28:34-38.
11. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11:319-326.
12. Charlson ME, Pompei P, Ales KL, Mac Kenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
13. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS:23). BMJ. 1998;316:823-828.
14. Harwood DT, Handelsman DJ. Development and validation of a sensitive liquid chromatography-tandem mass spectrometry assay to simultaneously measure androgens and estrogens in serum without derivatization. Clin Chim Acta. 2009;409:78-84.
15. R Core Team. R: a language and environment for statistical computing. 2013. Vienna, Austria: R Foundation for Statistical Computing. http://wwwR-project.org/.
16. Bates D, Maechler M, Bolker M. lme4: linear mixed-effects models using S4 classes. R package version 0.999999-2. 2013. http://CRANR-projectorg/package=lme4.
17. Spitzer M, Huang G, Basaria S, Travison TG, Bhasin S. Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol. 2013;9:414-424.
18. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2006;91:1995-2010.
19. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med. 2013;10:1612-1627.
20. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. J Sex Med. 2014;11:840-856.
21. Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 Study). Diabetes Care. 2011;34:828-837.
22. Giltay EJ, Tishova YA, Mskhalaya GJ, Gooren LJ, Saad F, Kalinchenko SY. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med. 2010;7:2572-2582.
23. Fernandez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95:2560-2575.
24. Ly LP, Sartorius G, Hull L, et al. Accuracy of calculated free testosterone formulae in men. Clin Endocrinol (Oxf). 2010;73:382-388.
25. Sikaris K, McLachlan RI, Kazlauskas R, de Kretser D, Holden CA, Handelsman DJ. Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays. J Clin Endocrinol Metab. 2005;90:5928-5936.
26. Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. NEnglJ Med. 2010;363:123-135.
27. Handelsman DJ. Global trends in testosterone prescribing, 2000-2011: expanding the spectrum of prescription drug misuse. Med J Aust. 2013;199:548-551.
28. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109-122.
29. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9:e85805.